Nigeria: Participants in Nigeria Vaccinated in First-Ever Phase 2 Lassa Fever Vaccine Clinical Trial, Sponsored By IAVI
[Nigeria Health Watch] The CEPI-funded study will evaluate the safety, tolerability, and immunogenicity of IAVI's single dose Lassa fever vaccine candidate (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - April 5, 2024 Category: African Health Tags: Health and Medicine Nigeria West Africa Source Type: news
The Most Exciting New Advances in Managing COPD
The Global Initiative for Chronic Obstructive Lung Disease, or GOLD, is the world’s preeminent COPD research and advocacy organization. Founded in 1997 in collaboration with the U.S. National Institutes of Health and the World Health Organization, one of GOLD’s stated aims is to “improve prevention and treatment of this lung disease.”
In its 2023 global strategy report, GOLD changed its definition of COPD—which many in the profession viewed as overdue. Specifically, the new definition emphasized the heterogeneity of COPD in terms of its underlying drivers and long-term disease course.
[ti...
Source: TIME: Health - March 18, 2024 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized freelance Source Type: news
Africans Can Solve the Disease that Haunts Us — Here’s How
It is critical that African scientists tackle African problems, and the reasons extend beyond access. Credit: Jeffrey Moyo/IPS. By Khisi MdluliBOSTON, US, Mar 15 2024 (IPS) I was born in Brakpan, Johannesburg, South Africa, and grew up in eSwatini (known then as Swaziland). People in these two countries share one predominant fear: unemployment. Other worries in these countries and others in the region include unwanted pregnancies, low income and food safety. The diseases that are dreaded the most are cancer and diabetes. Feared infectious diseases include HIV-AIDS, COVID and cholera.
Even though South Africa and eSwatini a...
Source: IPS Inter Press Service - Health - March 15, 2024 Category: International Medicine & Public Health Authors: Khisi Mdluli Tags: Africa Development & Aid Headlines Health Poverty & SDGs Source Type: news
‘I’m never going to be Tony’: Jeanne Marrazzo, Anthony Fauci’s successor, vows a new direction at NIAID
When Jeanne Marrazzo started her residency at the Yale New Haven Hospital in 1988, the world was a very different place. Marrazzo provided care for dying AIDS patients—mainly gay men and intravenous drug users and their sexual partners. “Stigma was alive and well and thriving, and in fact, really, really ugly at the time,” Marrazzo told an audience of young scientists on 3 March in Denver, just before the start of an HIV/AIDS conference. “You really sometimes had to work hard to get your patients what you needed. That made me interested in political and scientific advocacy and activism very early on.”
At th...
Source: ScienceNOW - March 8, 2024 Category: Science Source Type: news
What's Next for the World's First HIV Vaccine? What's Next for the World's First HIV Vaccine?
The last attempt in a generation of HIV vaccine development ended in disappointment, but investigators are starting over because they believe the human body can make antibodies for HIV.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - March 5, 2024 Category: Allergy & Immunology Tags: HIV/AIDS Source Type: news
Puzzling skin side effects stymie advance of promising HIV vaccine
One of the most promising attempts to reinvigorate the stalled quest for an HIV vaccine has hit a snag that might seem minor but has major consequences: delaying the larger trials needed to show whether the concept works. In small safety and immune tests of the innovative vaccine strategy, which relies on a series of messenger RNA (mRNA) shots, an unusually high percentage of recipients developed rashes, welts, or other skin irritations.
“We are taking this very seriously,” says Carl Dieffenbach, who heads the Division of AIDS at the National Institute of Allergy and Infectious Diseases, which funded a recent pha...
Source: ScienceNOW - March 1, 2024 Category: Science Source Type: news
A deadly viral illness is exploding in West Africa. Researchers are scrambling to figure out why
Reporting for this story was supported by the Pulitzer Center.
Irrua, Nigeria, and Kenema, Sierra Leone—
Sitting on a bench outside the Irrua Specialist Teaching Hospital (ISTH) in Edo state in southwestern Nigeria in September 2023, Muhammed Luqman Dagana recounted his ordeal earlier in the year with Lassa fever, a deadly hemorrhagic disease of West Africa. At first the 33-year-old wasn’t alarmed—his fever, headache, body aches, and cough were innocuous enough. A doctor at his local clinic gave him antibiotics for typhoid fever and antimalarial drugs. But his symptoms persisted, so he tried anoth...
Source: ScienceNOW - February 22, 2024 Category: Science Source Type: news
Uganda Sees Health Workforce Gains; Increases in Family Planning and Safe Deliveries at End of USAID Project
cbalesFebruary 19, 2024February 19, 2024Between 2017 and 2023, Uganda strengthened its health workforce and systems, improved health services, and championed locally led development in collaboration with IntraHealth ’sRegional Health Integration to Enhance Services in Eastern Uganda (RHITES-E) Activity.Led by IntraHealth in partnership with The AIDS Support Organization (TASO), Communication for Development Foundation Uganda (CDFU), Malaria Consortium, and Medic, the USAID-funded project worked closely with the government at the national and local levels to expand access to high-quality health services. RHITES-E also sup...
Source: IntraHealth International - February 19, 2024 Category: International Medicine & Public Health Authors: cbales Source Type: news
Last of the HIV Vaccine Trials Fails, Scientists Regroup Last of the HIV Vaccine Trials Fails, Scientists Regroup
Vaccinations were stopped after it became clear they would not be effective. " We cannot and will not lose hope that the world will have an effective HIV vaccine, " the International AIDS director said.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 18, 2023 Category: Consumer Health News Tags: HIV/AIDS Source Type: news
News at a glance: AI rules for Europe, vaccines for Africa, and a union for NIH early-career researchers
HEALTH EQUITY
A billion-dollar boost for vaccinemaking in Africa
Gavi, the Vaccine Alliance, has committed up to $1 billion to bolster Africa’s ability to sustainably produce its own doses of lifesaving vaccines. Manufacturers based in Africa produce only 1% of the vaccine doses used on the continent. Last week, Gavi announced that with money left over from the COVID-19 Vaccines Global Access Facility—an effort to provide an equitable distribution of COVID-19 vaccines—it would create the African Vaccine Manufacturing Accelerator (AVMA) to focus on preventing 11 priority infectious diseases. As ...
Source: ScienceNOW - December 14, 2023 Category: Science Source Type: news
Africa: HIV Vaccine Trial in Africa Halted Due to Ineffectiveness
[New Times] The initial attempt in Africa to assess the efficacy of two combined vaccines against HIV has been terminated as researchers determined that the intervention was ineffective. (Source: AllAfrica News: Health and Medicine)
Source: AllAfrica News: Health and Medicine - December 13, 2023 Category: African Health Tags: Africa HIV-Aids and STDs Health and Medicine Source Type: news
HIV Vaccine Trial in Africa Halted After Disappointing Data HIV Vaccine Trial in Africa Halted After Disappointing Data
A trial of an experimental HIV vaccine stopped early after preliminary data suggested it would not be effective in preventing infection, according to the trial ' s chief investigator.Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - December 9, 2023 Category: Infectious Diseases Tags: HIV/AIDS News Source Type: news
South Africa: Africa's First HIV Vaccine Trial Fails
[allAfrica] Harare -- An experimental HIV vaccine trial conducted in South Africa, Tanzania, and Uganda was prematurely terminated due to preliminary findings indicating the vaccine would not be successful in preventing infection, Reuters reports. (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - December 8, 2023 Category: Infectious Diseases Tags: HIV-Aids and STDs East Africa Health and Medicine South Africa Southern Africa Tanzania Uganda Source Type: news
'End of This Phase': Trial Halts Testing of HIV Vaccine Candidates
(MedPage Today) -- The PrEPVacc trial has stopped administering two investigational HIV vaccines that showed no efficacy in preventing infection, investigators announced on Wednesday during the International Conference on AIDS and STIs in Africa... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - December 7, 2023 Category: Infectious Diseases Source Type: news
HIV vaccine trial in Africa halted after disappointing initial results
African-led trial ended a year early as researchers conclude there is ‘little or no chance’ new combination vaccines cut HIV riskThefirst trial in Africa of two combination vaccines to prevent HIV has been halted after researchers concluded it was not working.The pre-exposure prophylaxis vaccine (PrEPVacc) was being tested on 1,500 people aged between 18 and 40 in Uganda, Tanzania and South Africa.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - December 7, 2023 Category: Science Authors: Samuel Okiror in Kampala Tags: Global development Aids and HIV Society Global health Uganda Tanzania South Africa Vaccines and immunisation World news Medical research Science Source Type: news
